Use SignalProfiler services to understand the effectiveness of compounds and drugs in relevant cells. A549 human lung carcinoma epithelial cells were serum starved for 3 hrs, then treated with 10 μM of the indicated clinical and developmental kinase inhibitors for 1 hr after which time the cells were treated with 100 ng/ml of EGF for 30 minutes. As anticipated the clinical EGFR inhibitors, Erlotinib, Gefitinib and Lapatanib, prevented EGFR phosphorylation (left panels) as well as the downstream activation of Erk-1/2 (right panel). Presumably, Sorafenib, a Raf inhibitor, prevents the activation of Erk-1/2 following EGF treatment by blocking the signal transduction through the Ras/Raf/MAPK pathway. Two independent wells were measured for each cell treatment condition.
